Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NanoVapor Biotech was a Houston-area affiliate/division of NanoVapor focused on nanotechnology-enabled antimicrobial surface protection rather than drug development. The company marketed OMNISOL and a 90-Day Surface Protection Treatment System designed to disinfect and protect high-touch surfaces against pathogens including bacteria and viruses in commercial, hospitality, transportation, educational, and medical settings. Public materials describe it as a technology solutions company using nanotechnology and EPA-registered antimicrobial formulations to provide persistent surface protection. Although it positioned itself in health- and pathogen-mitigation markets, the business appears to have operated more as a disinfection and environmental hygiene technology company than a therapeutic biotech developer. Available corporate records indicate the Texas entity is no longer active.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NanoVapor Biotech.